CELLULAR BIOMEDICINE GROUP, INC.
CMBG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CMBG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2020.
Tracking 2 pipeline candidates · 13 clinical trials for CELLULAR BIOMEDICINE GROUP, INC..
Run CELLULAR BIOMEDICINE GROUP, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CELLULAR BIOMEDICINE GROUP, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
6.0 months
D/E 4.37
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is CELLULAR BIOMEDICINE GROUP, INC.'s lead drug candidate?
CELLULAR BIOMEDICINE GROUP, INC.'s most advanced tracked candidate is afp-tcr-t (Phase 1) for hepatocellular carcinoma (HCC).
Who is the CEO of CELLULAR BIOMEDICINE GROUP, INC.?
On November is the chief executive officer of CELLULAR BIOMEDICINE GROUP, INC. (CMBG).
What therapeutic areas does CELLULAR BIOMEDICINE GROUP, INC. focus on?
CELLULAR BIOMEDICINE GROUP, INC. develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Dermatology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.